Growth hormone secretagogue receptor (GHSR) agonists like GHRP-2 are well known for their ability to produce large spikes in GHlevels. These spikes, while providing a number of interesting and important benefits in animal models, are also shortlived because thehalf life of most GHSR agonists is relatively short, To achieve long-term GH level increases, it is possible to use a GHRH analogue likemodified GRF. This provides a long-term increase in both basal and peak GH levels, but nowhere near the kind of GH spike that aGHSR agonists provides. in addition, animal models show that GHRH analogues are susceptible to somatostatin interference, whichcan offset increases in GH levels.
To get the best of both worlds, research into combining GHSR agonists and GHRH analogues is being undertaken. One particularhresearched combination is modified GRF with GHRP-2[4]. The synergy provides increased basal and peak levels of GH as wel asmeasured spikes that boost the benefits of both peptides in ways that simply increasing one or the other cannot
The net result of combining these peptides is improved GH release and substantial shifts in metabolism away from fat deposition.Lean body mass is increased substantially, insulin levels fall, and blood sugar becomes more requlatedl2i-4. There is even evidenceto show that both peptides, but particularly ipamorelin, can help to improve bone mineral density and bone healths.Acerca del autorInvestigación realizada por L. Edmiston, M.D. para PEPTIDE GURUS. L. Edmiston tiene un doctorado en medicina de la Facultad de Medicina de la Universidad Case Western Reserve y una licenciatura en ciencias. en biología molecular.Revista CientíficaAutorDr. Jan lzdebski has been listed as a noteworthy Chemist, researcher by Marguis Who'sWho. He attained a Master of Science from University Warsaw, Poland, 1959 and is aDoctor of Philosophy, University Warsaw, Poland, 1965, along with a Doctor of ScienceUniversity Warsaw, Poland, 1979. He studied how GRF 1-29 is more resistant toenzymatic degradation and how that affects its half-life.
Dr. Jan lzdebski is being referenced as one of the leading scientists involved in theresearch and development of GRF 1-29. In no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationshin, implied or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing the doctor is to acknowledge, reconize, and credit the exhaustiveresearch and development efforts conducted by the scientists studving this peptide. DrJan lzdebski is listed in [7]under the referenced citations.Recursos[1]M.Waelbroeck,P.Robberecht, D.H. Coy, J.-C. Camus. P. D. Neef. and J.Christophe, “Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRFAnalogs with Vasoactive Intestinal Peptide (VlP) Receptors of Rat Pancreas.Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP Antagonist,Endocrinology, vol.116,no.6,pp.2643-2649,Jun.1985.[PubMed]
[2] A.V. Schally, X. Zhang, R. Cai, J. M. Hare, R. Granata, and M. Bartoli, “Actionsand potential therapeutic applications of growth hormone-releasing hormoneagonists,” Endocrinology.[PubMed]
[3]E.Adeghate and A,S, Ponery, “Mechanism of ipamorelin-evoked insulin releasefrom the pancreas of normal and diabetic rats." Neuro Endocrinol Lett.. yol. 25.no6,pp.403-406,Dec.2004.[PubMed]
[4]D.E.Beck,W.B.Sweeney, M.D.McCarter, and lpamorelin 201 Study Group.Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimeticipamorelin for the management of postoperative ileus in bowe resection patients,Int. J.Colorectal Dis., vol.29,no.12,pp.1527-1534,Dec.2014.[PubMed]
[5]N.B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. ②rtoft, and H.Oxlund, “The growth hormone secretagoque ipamorelin counteracts glucocorticoid.induced decrease in bone formation of adult rats," Growth Horm. lGF Res. Off. J.Growth Horm.Res.Soc.Int.IGF Res.Soc., vol.11,no.5,pp.266-272,0ct. 2001[PubMed]
[6]J.Svensson et al., “The GH secretagogues ipamorelin and GH-releasingpeptide-6 increase bone mineral content in adult female rats,” J. Endocrinol.. vol.165,no.3, pp.569-577,Jun.2000.[PubMed]
[7] lzdebski, J., et al.“Potent Trypsin-Resistant HGH-RH Analogues." Journal of PEPTIDE GURUS : An Official Publication of the European Peptide Society[Semantics Scholar]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies onlv, In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
